Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

By V. Subbiah, J. Wolf, B. Konda, Hyunseok Kang, A. Spira, J. Weiss, M. Takeda, Yuichiro Ohe, S. Khan, K. Ohashi and 5 more. 2022